Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Twist Bioscience Corp (TWST) Price & Performance

Nerdwallet IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Twist Bioscience Corp — how do they compare? Nerdwallet Inc trades at $9.91 (market cap $625.17M), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 16.1× Nerdwallet Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Twist Bioscience Corp for 27 Days on average.

NRDSTWST
Market Cap
$625.17M$10.08B
Volume
1,321,3164,229,037
Sector
MediaHealth
52-Week High
$15.93$205.00
52-Week Low
$7.58$25.45
Typical Hold Time
45 Days27 Days
Enterprise Value
$539.47M$10.01B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.

Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.

The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NRDS
18% Buy82% Sell
Avg holding period · 45 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →